Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy (Q34725080)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy (English)

1 reference

Europe PubMed Central

4 August 2017

1 reference

based on heuristic

inferred from title

1

object named as

Orly Weinreb

1 reference

Europe PubMed Central

4 August 2017

Moussa B. H. Youdim

4

object named as

Moussa B H Youdim

1 reference

Europe PubMed Central

4 August 2017

author name string

Tamar Amit

2

1 reference

Europe PubMed Central

4 August 2017

Orit Bar-Am

3

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

1 December 2007

1 reference

Europe PubMed Central

4 August 2017

number of pages

14

1 reference

based on heuristic

inferred from page(s)

Annals of the New York Academy of Sciences

1 reference

Europe PubMed Central

4 August 2017

1122

1 reference

Europe PubMed Central

4 August 2017

155-168

1 reference

Europe PubMed Central

4 August 2017

Neurotrophins and neuronal differentiation in the central nervous system.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Recent progress in studies of neurotrophic factors and their clinical implications

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Neurotrophin signaling via Trks and p75.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Intracellular signaling pathways activated by neurotrophic factors

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Presenilin-1 mutation alters NGF-induced neurite outgrowth, calcium homeostasis, and transcription factor (AP-1) activation in PC12 cells.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

A glial cell line-derived neurotrophic factor (GDNF):tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Alginate encapsulated BDNF-producing fibroblast grafts permit recovery of function after spinal cord injury in the absence of immune suppression

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Point source concentration of GDNF may explain failure of phase II clinical trial

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Identification of potential compounds promoting BDNF production in nigral dopaminergic neurons: clinical implication in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Rasagiline improves quality of life in patients with early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

The essentiality of Bcl-2, PKC and proteasome–ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1,2 signaling pathways.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Gene transfer of glial cell-derived neurotrophic factor and cardiotrophin-1 protects PC12 cells from injury: involvement of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase pathways

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Synaptotagmin IV does not alter excitatory fast synaptic transmission or fusion pore kinetics in mammalian CNS neurons

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1403.011

21 January 2018

Identifiers

10.1196/ANNALS.1403.011

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34725080&oldid=2103254127"